Longevity Health Holdings Announces Continued Nasdaq Listing to Complete Merger With 20/20 Biolabs - Longevity Health Holdings (NASDAQ:XAGEW), Longevity Health Holdings (NASDAQ:XAGE)

Northrop Grumman (NOC) said it signed two multi-year framework agreements totaling over $3 billion to expand production of PAC 3 MSE and THAAD missile defense components. The article notes NOC shares at $585.87, with 12.33% 1-month return and 75% 5-year TSR, and cites a fair value estimate of $643.62 per share.

Nvidia (NVDA) and OpenAI are renegotiating a financing guarantee for a hyperscale data center campus in Ohio. The Wall Street Journal reports Nvidia cut the guarantee from $250B to under $120B, with support initially covering about 5 GW, and the rest decided later. SB Energy (SoftBank 9984.T) is developing the 10 GW site.

Nvidia scaled back its planned financial guarantee for an OpenAI data center project in Ohio, according to The Wall Street Journal. The guarantee was reduced to less than $120 billion from about $250 billion. The 10-gigawatt facility is being developed by SB Energy, a SoftBank subsidiary, to support OpenAI’s AI computing needs.

Nvidia revised its funding guarantee for a proposed OpenAI data center in Ohio, expected to initially back less than $120 billion versus $250 billion previously discussed, the Wall Street Journal reported. The chipmaker would provide a backstop only for the first phase. The change followed investor concerns about Nvidia’s financing risk exposure.

AbbVie (ABBV) says its neuroscience portfolio is expected to generate about $12.7 billion in revenue in 2026, up by $100 million after strong first-half performance. In Q2, neuroscience revenue rose 20.3% to $3.23 billion, led by Vraylar ($1.07B), therapeutic Botox ($1.04B), Ubrelvy and Qulipta ($742M), and Vyalev ($256M).

Oppenheimer upgraded Intuitive Surgical (ISRG) from “Perform” to “Outperform” and set a $500 price target, implying about 24.6% upside, citing robotic surgery growth and AI plans. The article notes Q2 revenue of $2.89B (vs $2.82B expected), EPS $2.80, da Vinci and Ion procedure growth, and ISRG guidance for da Vinci growth of 13.5% to 15.5%.